Results for tag: "Polypoidal Choroidal Vasculopathy Drug"

Polypoidal Choroidal Vasculopathy (PCV) is a degenerative eye disease that affects the choroid, a layer of blood vessels located between the retina and the sclera. It is characterized by the formation of polyps, which are abnormal, bulging blood vessels that can cause vision loss. Treatment for PCV typically involves the use of anti-VEGF drugs, which are drugs that block the growth of new blood vessels. These drugs are used to reduce the number of polyps and improve vision. The PCV drug market is a subset of the larger cardiovascular drug market. It is composed of drugs that are used to treat PCV, as well as other related conditions such as age-related macular degeneration and diabetic retinopathy. These drugs are typically administered via intravitreal injections, which are injections directly into the eye. The PCV drug market is highly competitive, with many companies offering their own versions of anti-VEGF drugs. Some of the major players in the market include Regeneron Pharmaceuticals, Novartis, Allergan, and Roche. Other companies such as Genentech, Bayer, and Santen Pharmaceuticals also offer PCV drugs. Show Less Read more